• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial
Share
Announcements, News, Trials

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

June 19, 2017
-
Posted by Webmaster

ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the European Cystic Fibrosis Society Conference, which took place between June 7th-10th in Seville. The study, which was conducted at Stanford University by Burgener and colleagues*, utilised the ProteaseTag® Active NE Immunoassay to associate Pf bacteriophage with higher levels of Pseudomonas aeruginosa and active neutrophil elastase in patients with CF.

At the same conference, the company presented data on the quantification of active neutrophil elastase (NE) using different sputum processing techniques. The study, with lead author Dr Charlene Robb, concluded that a basic sputum processing technique, which can be quickly and easily performed within a clinical setting, could be suitable for assessment of active NE, and may be combined with a rapid point-of-care test in the future, for quick clinical evaluation.

Dr David Ribeiro, CEO of ProAxsis, said: “It is very pleasing for the company to have expert centres utilising our ProteaseTag® Active NE Immunoassay in their ongoing research, especially when it is such a prestigious institution as Stanford. We’re delighted that our technology was beneficial to the important work they’re conducting”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

 

*Burgener, E, Yacob, A, Bollyky, P and Milla, C (2017) Pf Bacteriophage (Pf) in Pseudomonas aeruginosa (Pa) biofilms is associated with increased elastase in the sputum of patients with cystic fibrosis (CF).

June 19, 2017
No comments yet

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis abstracts at 2017 American Thoracic Society Conference

May 5, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …

Read More
May 5, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis signs partnership with a large US based biotechnology company

September 11, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for …

Read More
September 11, 2017
Posted by Webmaster
NEATstik®, News

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

September 4, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care …

Read More
September 4, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis gains further support from Innovate UK
NEXT POST →
ProAxsis CEO to present at Anglonordic Conference

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial - ProAxsis